<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35514985</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>09</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1664-3224</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <PubDate>
              <Year>2022</Year>
            </PubDate>
          </JournalIssue>
          <Title>Frontiers in immunology</Title>
          <ISOAbbreviation>Front Immunol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Case Report: Use of Obinutuzumab as an Alternative Monoclonal Anti-CD20 Antibody in a Patient With Refractory Immune Thrombocytopenia Complicated by Rituximab-Induced Serum Sickness and Anti-Rituximab Antibodies.</ArticleTitle>
        <Pagination>
          <StartPage>863177</StartPage>
          <MedlinePgn>863177</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">863177</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2022.863177</ELocationID>
        <Abstract>
          <AbstractText>Management of refractory immune thrombocytopenia frequently involves rituximab, a chimeric anti-CD20 monoclonal antibody, to target B cells and induce remission in most patients. However, neutralizing antibodies to rituximab that nullify therapeutic response and may lead to serum sickness have been rarely reported. Here, we present a case of a young adult woman with Evans syndrome treated with rituximab, complicated by the development of serum sickness, acute respiratory distress syndrome, and platelet refractoriness presumed secondary to neutralizing antibodies to rituximab. She was successfully treated with the humanized anti-CD20 monoclonal antibody, obinutuzumab, with subsequent symptom resolution. Additionally, a review of 10 previously published cases of serum-sickness associated with the use of rituximab for idiopathic thrombocytopenic purpura (ITP) is summarized. This case highlights that recognition of more subtle or rare symptoms of rituximab-induced serum sickness is important to facilitate rapid intervention.</AbstractText>
          <CopyrightInformation>Copyright © 2022 Blase, Frame, Michniacki and Walkovich.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Blase</LastName>
            <ForeName>Jennifer R</ForeName>
            <Initials>JR</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Frame</LastName>
            <ForeName>David</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, University of Michigan, Ann Arbor, MI, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Michniacki</LastName>
            <ForeName>Thomas F</ForeName>
            <Initials>TF</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Walkovich</LastName>
            <ForeName>Kelly</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pediatrics, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, United States.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D002363">Case Reports</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>04</Month>
          <Day>19</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Front Immunol</MedlineTA>
        <NlmUniqueID>101560960</NlmUniqueID>
        <ISSNLinking>1664-3224</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D058846">Antibodies, Monoclonal, Murine-Derived</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>4F4X42SYQ6</RegistryNumber>
          <NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>O43472U9X8</RegistryNumber>
          <NameOfSubstance UI="C543332">obinutuzumab</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058846" MajorTopicYN="N">Antibodies, Monoclonal, Murine-Derived</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016553" MajorTopicYN="Y">Purpura, Thrombocytopenic, Idiopathic</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012713" MajorTopicYN="Y">Serum Sickness</DescriptorName>
          <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">ITP (idiopathic thrombocytopenic purpura)</Keyword>
        <Keyword MajorTopicYN="N">case report</Keyword>
        <Keyword MajorTopicYN="N">obinutuzumab</Keyword>
        <Keyword MajorTopicYN="N">rituximab</Keyword>
        <Keyword MajorTopicYN="N">serum sickness</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>5</Hour>
          <Minute>31</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35514985</ArticleId>
        <ArticleId IdType="pmc">PMC9061985</ArticleId>
        <ArticleId IdType="doi">10.3389/fimmu.2022.863177</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. . American Society of Hematology 2019 Guidelines for Immune Thrombocytopenia. Blood Adv (2019) 3(23):3829–66. doi: 10.1182/bloodadvances.2019000966
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/bloodadvances.2019000966</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lucchini E, Zaja F, Bussel J. Rituximab in the Treatment of Immune Thrombocytopenia: What Is the Role of This Agent in 2019? Haematologica (2019) 104(6):1124–35. doi: 10.3324/haematol.2019.218883
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3324/haematol.2019.218883</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Hasan A, Michel M, Patel V, Stasi R, Cunningham–Rundless S, Leonard JP, et al. . Repeated Courses of Rituximab in Chronic ITP: Three Different Regimens. Am J Hematol (2009) 84(10):661–5. doi: 10.1002/ajh.21512
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.21512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bayer G, Agier MS, Lioger B, Lepelley M, Zenut M, Lanoue MC, et al. . Rituximab-Induced Serum Sickness Is More Frequent in Autoimmune Diseases as Compared to Hematological Malignancies: A French Nationwide Study. Eur J Intern Med (2019) 67:59–64. doi: 100.1016/j.ejim.2019.06.009
</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">31279430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bennett CM, Rogers ZR, Kinnamon DD, Bussel JB, Mahoney DH, Abshire TC, et al. . Prospective Phase 1/2 Study of Rituximab in Childhood and Adolescent Chronic Immune Thrombocytopenic Purpura. Blood (2006) 107(7):2639–42. doi: 10.1182/blood-2005-08-3518
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2005-08-3518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wang J, Wiley JM, Luddy R, Greenberg J, Feuerstein MA, Bussel JB. Chronic Immune Thrombocytopenic Purpura in Children: Assessment of Rituximab Treatment. J Pediatr (2005) 146(2):217–21. doi: 10.1016/j.jpeds.2004.09.004
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jpeds.2004.09.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Karmacharya P, Poudel DR, Pathak R, Donato AA, Ghimire S, Giri S, et al. . Rituximab-Induced Serum Sickness: A Systematic Review. Semin Arthritis Rheum (2015) 45(3):334–40. doi: 10.1016/j.semarthrit.2015.06.014
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semarthrit.2015.06.014</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Bayram MT, Soylu A, Kavukcu S. Rituximab-Induced Serum Sickness and Anaphylaxis in a Child With Nephrotic Syndrome. Turk J Pediatr (2020) 62(5):884–8. doi: 10.24953/turkjped.2020.05.025
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.24953/turkjped.2020.05.025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Herishanu Y, Levi S, Kamdjou T, Bornstein Y, Ram R, Benyamini N, et al. . Obinutuzumab in the Treatment of Autoimmune Haemolytic Anaemia and Immune Thrombocytopenia in Patients With Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma. Br J Haematol (2021) 192(1):e1–4. doi: 10.1111/bjh.17105
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.17105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Godeau B, Porcher R, Fain O, Lefrere F, Fenaux P, Cheze S, et al. . Rituximab Efficacy and Safety in Adult Splenectomy Candidates With Chronic Immune Thrombocytopenic Purpura: Results of a Prospective Multicenter Phase 2 Study. Blood (2008) 112(4):999–1004. doi: 10.1182/blood-2008-01-131029
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2008-01-131029</ArticleId>
            <ArticleId IdType="pubmed">18463354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Goto S, Goto H, Tanoshima R, Kato H, Takahashi H, Sekiguchi O, et al. . Serum Sickness With an Elevated Level of Human Anti-Chimeric Antibody Following Treatment With Rituximab in a Child With Chronic Immune Thrombocytopenic Purpura. Int J Hematol (2009) 89(3):305–9. doi: 10.1007/s12185-009-0269-6
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12185-009-0269-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Medeot M, Zaja F, Vianelli N, Battista M, Baccarani M, Patriarca F, et al. . Rituximab Therapy in Adult Patients With Relapsed or Refractory Immune Thrombocytopenic Purpura: Long-Term Follow-Up Results. Eur J Haematol (2008) 81(3):165–9. doi: 10.1111/j.1600-0609.2008.01100.x
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1600-0609.2008.01100.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Herishanu Y. Rituximab-Induced Serum Sickness. Am J Hematol (2002) 70(4):329. doi: 10.1002/ajh.10127
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ajh.10127</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Manko A, Besecker B. Plasmapheresis Reverses ARDS in Rituximab Induced Serum Sickness. Chest (2014) 146(4):269A. doi: 10.1378/chest.1958613
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1378/chest.1958613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Paul F, Cartron G. Infusion-Related Reactions to Rituximab: Frequency, Mechanisms and Predictors. Expert Rev Clin Immunol (2019) 15(4):383–9. doi: 10.1080/1744666X.2019.1562905
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/1744666X.2019.1562905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Picard M, Galvao VR. Current Knowledge and Management of Hypersensitivity Reactions to Monoclonal Antibodies. J Allergy Clin Immunol Pract (2017) 5(3):600–9. doi: 10.1016/j.jaip.2016.12.001
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jaip.2016.12.001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Rixe N, Tavarez MM. Serum Sickness. Treasure Island. FL: StatPearls;  (2021).</Citation>
        </Reference>
        <Reference>
          <Citation>
Klein C, Lammens A, Schafer W, Georges G, Schwaiger M, Mossner E, et al. . Epitope Interactions of Monoclonal Antibodies Targeting CD20 and Their Relationship to Functional Properties. MAbs (2013) 5(1):22–33. doi: 10.4161/mabs.22771
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/mabs.22771</ArticleId>
            <ArticleId IdType="pmc">PMC3564883</ArticleId>
            <ArticleId IdType="pubmed">23211638</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Boyer-Suavet S, Adreani M, Lateb M, Savenkoff B, Brglez V, Benzaken S, et al. . Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab. Front Immunol (2019) 10:3069. doi: 10.3389/fimmu.2019.03069
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.03069</ArticleId>
            <ArticleId IdType="pmc">PMC6970431</ArticleId>
            <ArticleId IdType="pubmed">31998325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Harding FA, Stickler MM, Razo J, DuBridge RB. The Immunogenicity of Humanized and Fully Human Antibodies: Residual Immunogenicity Resides in the CDR Regions. MAbs (2010) 2(3):256–65. doi: 10.4161/mabs.2.3.11641
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/mabs.2.3.11641</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fouda GE, Bavbek S. Rituximab Hypersensitivity: From Clinical Presentation to Management. Front Pharmacol (2020) 11:572863. doi: 10.3389/fphar.2020.572863
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fphar.2020.572863</ArticleId>
            <ArticleId IdType="pmc">PMC7508176</ArticleId>
            <ArticleId IdType="pubmed">33013416</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
